James Kirkland says Senolytics has a 20% success rate
Cellular senescence, one of the hallmarks associated with aging is when cells that are aging do not die the normal way (apoptosis), but instead start to accumulate within our bodies. These \”senescent cells\” are implicated in a number of diseases, including Alzheimer’s, arthritis, cancer, atherosclerosis and diabetes. Senescence is not only a part of aging, but can also occur when people become frail and develop multiple illnesses.
A team of Mayo Clinic researchers led by Dr James L Kirkland published a seminal article in Aging Cell in 2015 that introduced a class of drugs known as senolytics. These drugs were selected based on the belief that removing senescent cell may improve human healthspan.
Longevity. Technology: Since the discovery or creation of the first senolytics hundreds more have been discovered or created. Senotherapeutics has become one of the most popular areas of longevity research, with clinical trials underway and companies seeking senolytic treatments for a variety of age-related diseases. What does the man behind the therapy he created think of it? We bring you the unique perspective of Dr Kirkland on the world senolytics in the first of two posts.
Source:
